{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:48:42Z","timestamp":1792244922030,"version":"4.4.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s11102-022-01257-5","type":"journal-article","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T17:02:52Z","timestamp":1659027772000},"page":"810-818","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Treatment of non-functioning pituitary adenoma with cabergoline: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"25","author":[{"given":"Mayra Souza","family":"Botelho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00cdtalo Antunes","family":"Franzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9316-4167","authenticated-orcid":false,"given":"Vania dos Santos","family":"Nunes-Nogueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar Luiz","family":"Boguszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,28]]},"reference":[{"issue":"1","key":"1257_CR1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ecl.2007.10.011","volume":"37","author":"ME Molitch","year":"2008","unstructured":"Molitch ME (2008) Nonfunctioning pituitary tumors and pituitary incidentalomas. Endocrinol Metab Clin North Am 37(1):151\u2013171","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"7","key":"1257_CR2","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.endinu.2017.05.009","volume":"64","author":"M Mercado","year":"2017","unstructured":"Mercado M, Melgar V, Salame L, Cuenca D (2017) Clinically non-functioning pituitary adenomas: Pathogenic, diagnostic and therapeutic aspects. Endocrinologia, Diabetes y Nutricion 64(7):384\u2013395","journal-title":"Endocrinologia, Diabetes y Nutricion"},{"key":"1257_CR3","first-page":"1","volume":"13","author":"MH AlMalki","year":"2020","unstructured":"AlMalki MH, Ahmad MM, Brema I, AlDahmani KM, Pervez N, Al-Dandan S et al (2020) Contemporary management of clinically non-functioning pituitary adenomas: a clinical review. Clin Med Insights 13:1\u201313","journal-title":"Clin Med Insights"},{"issue":"4","key":"1257_CR4","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.nec.2019.05.006","volume":"30","author":"CJ Farrell","year":"2019","unstructured":"Farrell CJ, Garzon-Muvdi T, Fastenberg JH, Nyquist GG, Rabinowitz MR, Rosen MR et al (2019) Management of nonfunctioning recurrent pituitary adenomas. Neurosurg Clin N Am 30(4):473\u2013482","journal-title":"Neurosurg Clin N Am"},{"issue":"1","key":"1257_CR5","doi-asserted-by":"publisher","first-page":"D1","DOI":"10.1530\/EJE-19-0058","volume":"181","author":"P Chanson","year":"2019","unstructured":"Chanson P, Dormoy A, Dekkers OM (2019) Use of radiotherapy after pituitary surgery for non-functioning pituitary adenomas. Eur J Endocrinol 181(1):D1\u2013D13","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"1257_CR6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s42000-018-0070-0","volume":"18","author":"M Tampourlou","year":"2019","unstructured":"Tampourlou M, Karapanou O, Vassiliadi DA, Tsagarakis S (2019) Medical therapy for non-functioning pituitary tumors-a critical approach. Hormones 18(2):117\u2013126","journal-title":"Hormones"},{"issue":"4","key":"1257_CR7","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1210\/jc.2003-030859","volume":"89","author":"R Pivonello","year":"2004","unstructured":"Pivonello R, Matrone C, Filippella M, Cavallo LM, Di Somma C, Cappabianca P et al (2004) Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment. J Clin Endocrinol Metab 89(4):1674\u20131683","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1257_CR8","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1159\/000504000","volume":"110","author":"S Lin","year":"2020","unstructured":"Lin S, Zhang A, Zhang X, Wu ZB (2020) Treatment of pituitary and other tumours with cabergoline: new mechanisms and potential broader applications. Neuroendocrinology 110(6):477\u2013488","journal-title":"Neuroendocrinology"},{"issue":"4","key":"1257_CR9","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1517\/14740338.2016.1151493","volume":"15","author":"RS Auriemma","year":"2016","unstructured":"Auriemma RS, Grasso LF, Pivonello R, Colao A (2016) The safety of treatments for prolactinomas. Expert Opin Drug Saf 15(4):503\u2013512","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"1257_CR10","doi-asserted-by":"publisher","first-page":"D11","DOI":"10.1530\/EJE-21-0344","volume":"185","author":"Y Greenman","year":"2021","unstructured":"Greenman Y, Bronstein MD (2021) Cabergoline should be attempted in progressing non-functioning pituitary macroadenoma. Eur J Endocrinol 185(4):D11-d20","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"1257_CR11","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097","journal-title":"PLoS Med"},{"issue":"1","key":"1257_CR12","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan-a web and mobile app for systematic reviews. Syst Rev 5(1):210","journal-title":"Syst Rev"},{"issue":"10","key":"1257_CR13","first-page":"2127","volume":"18","author":"Z Munn","year":"2020","unstructured":"Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A et al (2020) Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth 18(10):2127\u20132133","journal-title":"JBI Evid Synth"},{"issue":"1","key":"1257_CR14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/2049-3258-72-39","volume":"72","author":"VN Nyaga","year":"2014","unstructured":"Nyaga VN, Arbyn M, Aerts M (2014) Metaprop: a Stata command to perform meta-analysis of binomial data. Arch Public Health 72(1):39","journal-title":"Arch Public Health"},{"key":"1257_CR15","unstructured":"National Library of Medicine (U.S.). (2014). Dopamine agonist treatment of non-functioning pituitary adenomas. Identifier NCT02288962. https:\/\/clinicaltrials.gov\/show\/NCT02288962 (2014). Accessed 20 Nov 2020"},{"issue":"1","key":"1257_CR16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1365-2265.2005.02295.x","volume":"63","author":"Y Greenman","year":"2005","unstructured":"Greenman Y, Tordjman K, Osher E, Veshchev I, Shenkerman G, Reider G II et al (2005) Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour remnant growth. Clin Endocrinol 63(1):39\u201344","journal-title":"Clin Endocrinol"},{"issue":"5","key":"1257_CR17","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/cen.12684","volume":"82","author":"L Vieira Neto","year":"2015","unstructured":"Vieira Neto L, Wildemberg LE, Moraes AB, Colli LM, Kasuki L, Marques NV et al (2015) Dopamine receptor subtype 2 expression profile in nonfunctioning pituitary adenomas and in vivo response to cabergoline therapy. Clin Endocrinol 82(5):739\u2013746","journal-title":"Clin Endocrinol"},{"issue":"5","key":"1257_CR18","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1530\/eje.1.02281","volume":"155","author":"WW de Herder","year":"2006","unstructured":"de Herder WW, Reijs AE, Feelders RA, van Aken MO, Krenning EP, Tanghe HL et al (2006) Dopamine agonist therapy of clinically non-functioning pituitary macroadenomas. Is there a role for 123I-epidepride dopamine D2 receptor imaging? Eur J Endocrinol 155(5):717\u201323","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"1257_CR19","doi-asserted-by":"publisher","first-page":"159","DOI":"10.4158\/EP13182.OR","volume":"20","author":"E Robenshtok","year":"2014","unstructured":"Robenshtok E, Benbassat CA, Hirsch D, Tzvetov G, Cohen ZR, Iraqi HM et al (2014) Clinical course and outcome of nonfunctioning pituitary adenomas in the elderly compared with younger age groups. Endocr Pract 20(2):159\u2013164","journal-title":"Endocr Pract"},{"issue":"4","key":"1257_CR20","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/00005792-199907000-00004","volume":"78","author":"J Gsponer","year":"1999","unstructured":"Gsponer J, De Tribolet N, D\u00e9ruaz JP, Janzer R, Usk\u00e9 A, Mirimanoff RO et al (1999) Diagnosis, treatment, and outcome of pituitary tumors and other abnormal intrasellar masses. Retrospective analysis of 353 patients. Medicine 78(4):236\u201369","journal-title":"Medicine"},{"issue":"2","key":"1257_CR21","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1530\/acta.0.1160253","volume":"116","author":"RW Gasser","year":"1987","unstructured":"Gasser RW, Mueller-Holzner E, Skrabal F, Finkenstedt G, Mayr U, Tabarelli M et al (1987) Macroprolactinomas and functionless pituitary tumours. Immunostaining and effect of dopamine agonist therapy. Acta Endocrinol 116(2):253\u20139","journal-title":"Acta Endocrinol"},{"issue":"4","key":"1257_CR22","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1046\/j.1365-2265.2000.00951.x","volume":"52","author":"A Colao","year":"2000","unstructured":"Colao A, Ferone D, Lastoria S, Cerbone G, Di Sarno A, Di Somma C et al (2000) Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide. Clin Endocrinol 52(4):437\u2013445","journal-title":"Clin Endocrinol"},{"issue":"2","key":"1257_CR23","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/COC.0000000000000505","volume":"42","author":"RL Batista","year":"2019","unstructured":"Batista RL, Musolino NRC, Cescato VAS, da Silva GO, Medeiros RSS, Herkenhoff CGB et al (2019) Cabergoline in the management of residual nonfunctioning pituitary adenoma: a single-center, open-label, 2-year randomized clinical trial. Am J Clin Oncol 42(2):221\u2013227","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"1257_CR24","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1530\/EJE-16-0206","volume":"175","author":"Y Greenman","year":"2016","unstructured":"Greenman Y, Cooper O, Yaish I, Robenshtok E, Sagiv N, Jonas-Kimchi T et al (2016) Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists. Eur J Endocrinol 175(1):63\u201372","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"1257_CR25","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s11102-012-0403-y","volume":"16","author":"EC Garcia","year":"2013","unstructured":"Garcia EC, Naves LA, Silva AO, De Castro LF, Casulari LA, Azevedo MF (2013) Short-term treatment with cabergoline can lead to tumor shrinkage in patients with nonfunctioning pituitary adenomas. Pituitary 16(2):189\u2013194","journal-title":"Pituitary"},{"issue":"3","key":"1257_CR26","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1023\/A:1015366923810","volume":"4","author":"T Lohmann","year":"2001","unstructured":"Lohmann T, Trantakis C, Biesold M, Prothmann S, Guenzel S, Schober R et al (2001) Minor tumour shrinkage in nonfunctioning pituitary adenomas by long-term treatment with the dopamine agonist cabergoline. Pituitary 4(3):173\u2013178","journal-title":"Pituitary"},{"key":"1257_CR27","doi-asserted-by":"crossref","unstructured":"Vargas G, Gonzalez B, Ramirez C, Ferreira A, Espinosa E, Mendoza V et al (2015) Clinical characteristics and treatment outcome of 485 patients with nonfunctioning pituitary macroadenomas. Int J Endocrinol","DOI":"10.1155\/2015\/756069"},{"issue":"3","key":"1257_CR28","doi-asserted-by":"publisher","first-page":"R113","DOI":"10.1530\/EJE-17-0216","volume":"177","author":"Y Greenman","year":"2017","unstructured":"Greenman Y (2017) Management of endocrine disease: Present and future perspectives for medical therapy of nonfunctioning pituitary adenomas. Eur J Endocrinol 177(3):R113\u2013R124","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"1257_CR29","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/cen.13791","volume":"89","author":"MJ Levy","year":"2018","unstructured":"Levy MJ, Robertson IJ, Khalk N, Vitello S, Reddy N, Bhake R et al (2018) Long-term follow-up of a large prospective cohort of patients with nonfunctioning pituitary adenomas: the outcome of a conservative management policy. Clin Endocrinol 89(3):354\u2013359","journal-title":"Clin Endocrinol"},{"issue":"6","key":"1257_CR30","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/jc.2016-4061","volume":"102","author":"M Tampourlou","year":"2017","unstructured":"Tampourlou M, Ntali G, Ahmed S, Arlt W, Ayuk J, Byrne JV et al (2017) Outcome of nonfunctioning pituitary adenomas that regrow after primary treatment: a study from two large UK centers. J Clin Endocrinol Metab 102(6):1889\u20131897","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1257_CR31","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1159\/000339823","volume":"96","author":"Y Chen","year":"2012","unstructured":"Chen Y, Wang CD, Su ZP, Chen YX, Cai L, Zhuge QC et al (2012) Natural history of postoperative nonfunctioning pituitary adenomas: a systematic review and meta-analysis. Neuroendocrinology 96(4):333\u2013342","journal-title":"Neuroendocrinology"},{"issue":"10","key":"1257_CR32","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.1210\/jc.2008-0643","volume":"93","author":"OM Dekkers","year":"2008","unstructured":"Dekkers OM, Pereira AM, Romijn JA (2008) Treatment and follow-up of clinically nonfunctioning pituitary macroadenomas. J Clin Endocrinol Metab 93(10):3717\u20133726","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1257_CR33","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s11102-018-0868-4","volume":"21","author":"G Minniti","year":"2018","unstructured":"Minniti G, Flickinger J, Tolu B, Paolini S (2018) Management of nonfunctioning pituitary tumors: radiotherapy. Pituitary 21(2):154\u2013161","journal-title":"Pituitary"},{"issue":"7","key":"1257_CR34","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1002\/1097-0142(19931001)72:7<2227::AID-CNCR2820720727>3.0.CO;2-I","volume":"72","author":"RW Tsang","year":"1993","unstructured":"Tsang RW, Laperriere NJ, Simpson WJ, Brierley J, Panzarella T, Smyth HS (1993) Glioma arising after radiation therapy for pituitary adenoma. A report of four patients and estimation of risk. Cancer 72(7):2227\u201333","journal-title":"Cancer"},{"issue":"2","key":"1257_CR35","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1210\/jc.2004-1152","volume":"90","author":"G Minniti","year":"2005","unstructured":"Minniti G, Traish D, Ashley S, Gonsalves A, Brada M (2005) Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years. J Clin Endocrinol Metab 90(2):800\u2013804","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1257_CR36","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1046\/j.1365-2265.1997.d01-1749.x","volume":"46","author":"B B\u00fclow","year":"1997","unstructured":"B\u00fclow B, Hagmar L, Mikoczy Z, Nordstr\u00f6m CH, Erfurth EM (1997) Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol 46(1):75\u201381","journal-title":"Clin Endocrinol"},{"issue":"6","key":"1257_CR37","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1046\/j.1365-2265.2002.01570.x","volume":"57","author":"M Brada","year":"2002","unstructured":"Brada M, Ashley S, Ford D, Traish D, Burchell L, Rajan B (2002) Cerebrovascular mortality in patients with pituitary adenoma. Clin Endocrinol 57(6):713\u2013717","journal-title":"Clin Endocrinol"},{"issue":"5","key":"1257_CR38","first-page":"1310","volume":"75","author":"TW de Bruin","year":"1992","unstructured":"de Bruin TW, Kwekkeboom DJ, Van\u2019t Verlaat JW, Reubi JC, Krenning EP, Lamberts SW et al (1992) Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro. J Clin Endocrinol Metab 75(5):1310\u20131317","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1257_CR39","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1385\/ENDO:20:3:279","volume":"20","author":"A Colao","year":"2003","unstructured":"Colao A, Filippella M, Di Somma C, Manzi S, Rota F, Pivonello R et al (2003) Somatostatin analogs in treatment of non-growth hormone-secreting pituitary adenomas. Endocrine 20(3):279\u2013283","journal-title":"Endocrine"},{"issue":"4","key":"1257_CR40","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s11102-011-0370-8","volume":"15","author":"A Fusco","year":"2012","unstructured":"Fusco A, Giampietro A, Bianchi A, Cimino V, Lugli F, Piacentini S et al (2012) Treatment with octreotide LAR in clinically non-functioning pituitary adenoma: results from a case-control study. Pituitary 15(4):571\u2013578","journal-title":"Pituitary"},{"issue":"2","key":"1257_CR41","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s11102-016-0745-y","volume":"20","author":"C Halevy","year":"2017","unstructured":"Halevy C, Whitelaw BC (2017) How effective is temozolomide for treating pituitary tumours and when should it be used? Pituitary 20(2):261\u2013266","journal-title":"Pituitary"},{"issue":"4","key":"1257_CR42","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1677\/ERC-08-0181","volume":"15","author":"A Colao","year":"2008","unstructured":"Colao A, Di Somma C, Pivonello R, Faggiano A, Lombardi G, Savastano S (2008) Medical therapy for clinically non-functioning pituitary adenomas. Endocr Relat Cancer 15(4):905\u2013915","journal-title":"Endocr Relat Cancer"},{"key":"1257_CR43","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01071","author":"CE Stiles","year":"2018","unstructured":"Stiles CE, Tetteh-Wayoe ET, Bestwick J, Steeds RP, Drake WM (2018) A meta-analysis of the prevalence of cardiac valvulopathy in hyperprolactinemic patients treated with Cabergoline. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/jc.2018-01071","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"1257_CR44","doi-asserted-by":"publisher","first-page":"e3507","DOI":"10.1210\/clinem\/dgaa497","volume":"105","author":"MD Ilie","year":"2020","unstructured":"Ilie MD, Raverot G (2020) Treatment options for gonadotroph tumors: current state and perspectives. J Clin Endocrinol Metab 105(10):e3507\u2013e3518","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1257_CR45","doi-asserted-by":"publisher","first-page":"695","DOI":"10.3390\/jcm8050695","volume":"8","author":"M Sato","year":"2019","unstructured":"Sato M, Tamura R, Tamura H et al (2019) Analysis of tumor angiogenesis and immune microenvironment in non-functional pituitary endocrine tumors. J Clin Med 8(5):695","journal-title":"J Clin Med"},{"issue":"1","key":"1257_CR46","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s40478-019-0830-3","volume":"7","author":"P Marques","year":"2019","unstructured":"Marques P, Barry S, Carlsen E et al (2019) Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours. Acta Neuropathol Commun 7(1):172","journal-title":"Acta Neuropathol Commun"},{"issue":"6","key":"1257_CR47","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1111\/jcpt.13460","volume":"46","author":"MM Fachi","year":"2021","unstructured":"Fachi MM, de Deus Bueno L, de Oliveira DC, da Silva LL, Bonetti AF (2021) Efficacy and safety in the treatment of hyperprolactinemia: a systematic review and network meta-analysis. J Clin Pharm Ther 46(6):1549\u201356","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"1257_CR48","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12902-020-0507-8","volume":"20","author":"A Budayr","year":"2020","unstructured":"Budayr A, Tan TC, Lo JC, Zaroff JG, Tabada GH, Yang J et al (2020) Cardiac valvular abnormalities associated with use and cumulative exposure of cabergoline for hyperprolactinemia: the CATCH study. BMC Endocr Disord 20(1):25","journal-title":"BMC Endocr Disord"},{"issue":"1","key":"1257_CR49","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s11102-011-0339-7","volume":"15","author":"CL Boguszewski","year":"2012","unstructured":"Boguszewski CL, dos Santos CM, Sakamoto KS, Marini LC, de Souza AM, Azevedo M (2012) A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas. Pituitary 15(1):44\u201349","journal-title":"Pituitary"},{"issue":"2","key":"1257_CR50","doi-asserted-by":"publisher","first-page":"e711","DOI":"10.1210\/clinem\/dgaa882","volume":"106","author":"CE Stiles","year":"2021","unstructured":"Stiles CE, Lloyd G, Bhattacharyya S, Steeds RP, Boomla K, Bestwick JP et al (2021) Incidence of cabergoline-associated valvulopathy in primary care patients with prolactinoma using hard cardiac endpoints. J Clin Endocrinol Metab 106(2):e711\u2013e720","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-022-01257-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-022-01257-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-022-01257-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T01:03:00Z","timestamp":1668992580000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-022-01257-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,28]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1257"],"URL":"https:\/\/doi.org\/10.1007\/s11102-022-01257-5","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,28]]},"assertion":[{"value":"8 July 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}